Gerresheimer AG reduces 2026 outlook amid project delays
Shares of Gerresheimer AG fell on Monday, trading down about 0.85%, after the company announced a downgrade to its 2026 financial guidance. The German pharmaceutical packaging manufacturer now expects 2026 revenue, before any mergers and acquisitions or refinancing activities, to be in the lower half of its previously indicated range of €2.3 billion to €2.4 billion. Adjusted EBITDA margin guidance has been trimmed to approximately 17 %–18 %, compared with the earlier outlook of 18 %–19 %. Free cash flow is projected to be negative, between €‑50 million and €‑100 million, whereas earlier guidance anticipated a modestly positive cash flow.
The downgrade was attributed to project delays on the part of customers and operational challenges, including difficulties related to production ramp‑ups. Despite these setbacks, Gerresheimer said the sale process for its Centor business remains on track and is still expected to close by the end of fiscal year 2026. The company also aims to complete a comprehensive debt refinancing before that same deadline.